Silo Pharma, Inc. - Common Stock (SILO)

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

With developmental-stage Silo Pharma inking a partnership to forward PTSD drugs, SILO stock shot higher on the credibility boost.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.

Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and fibromyalgia.

Silo Pharma Inc.'s stock (NASDAQ: SILO) is on the the rise Wednesday following the company's announcement that it has been awarded a U.S. patent for its PTSD treatment titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females."

Silo Pharma stock is rising after announcing a collaboration with Kymanox to develop a subcutaneous insertion device for its SP-26 chronic pain treatment.

Silo Pharma stock soared on high trading volume after announcing a partnership with Resyca BV for developing an intranasal PTSD treatment. The collaboration aims to enhance drug delivery to the brain, for faster therapeutic benefits and improved safety.